About: Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients
Creator	Agape, Philippe Autran, Brigitte Bay, Jacques-Olivier Dhédin, Nathalie Krivine, Anne Le Corre, Nicole Le Goff, Jérôme Lioure, Bruno Mallet, Alain Ribaud, Patricia Rubio, Marie-Thérèse Thiébaut, Anne
Source	Elsevier; Medline; PMC
abstract	Abstract Background The present study evaluated immunogenicity and tolerance of two-dose influenza A/H1N1pdm09 vaccination in allogeneic hematopoietic stem cell transplantation (HSCT) recipients, and compared the vaccine-induced humoral response to that triggered by natural infection in another group of HSCT patients. Methods Adult allogeneic HSCT recipients vaccinated with two doses of influenza A/H1N1pdm09 vaccine, separated by 3 weeks, and patients with proven influenza A/H1N1pdm09 infection were included. Antibody responses were measured by hemagglutination-inhibition assay 1) on days 0, 21, 42 and 6 months after the first vaccine injection in vaccinated patients and 2) before pandemic and after influenza A/H1N1pdm09 infection, in patients presented natural infection. Results At baseline, 3% of 59 recipients of adjuvanted vaccine and 0% of 20 infected patients were seroprotected (antibody titer≥1/40). Seroprotection rate observed 42 days after vaccination was not different from that observed after natural infection (66% and 60% respectively, p =0.78). In vaccinated patients, seroprotection rate increased significantly from 54% to 66% between day 21 and 42 (p =0.015). Moreover, after 6 months, seroprotection rate in 21 vaccinated patients was similar to that observed in 10 infected patients evaluated at least 76 days after infection (D76–217) (60% and 81% respectively, p =0.2). In multivariate analysis, no immunosuppressive treatment or chronic graft-versus-host disease (GVHD) and longer time between transplantation and vaccination/infection were associated with a stronger humoral response. The adjuvanted vaccine was safe with low rate of GVHD worsening. Conclusion In HSCT recipients, two doses of influenza A/H1N1pdm09 adjuvanted vaccine were safe and induced a humoral response comparable to that triggered by natural infection in these patients.
has issue date	2014-01-23(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2013.11.073
bibo:pmid	24333120
has license	els-covid
sha1sum (hex)	fa9d5bbf9793d156a4a0f58e8dc9ba221378ee89
schema:url	https://doi.org/10.1016/j.vaccine.2013.11.073
resource representing a document's title	Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients
has PubMed Central identifier	PMC7115606
has PubMed identifier	24333120
schema:publication	Vaccine
resource representing a document's body	covid:fa9d5bbf9793d156a4a0f58e8dc9ba221378ee89#body_text
is schema:about of	named entity 'ADJUVANTED' named entity 'natural' named entity 'patients' named entity 'adjuvanted' named entity 'infection' named entity 'day' named entity 'compared' named entity 'triggered' named entity 'transplantation' named entity 'infected' named entity 'vaccination' named entity 'doses' named entity 'observed' named entity 'natural' named entity 'adjuvanted' named entity 'observed' named entity 'DOSES' named entity 'METHODS' named entity 'THESE' named entity 'RESULTS' named entity 'RESPONSES' named entity 'LOW' named entity 'TREATMENT' named entity 'HEMAGGLUTINATION-INHIBITION ASSAY' named entity 'INCREASED' named entity 'DOSES' named entity 'TIME' named entity 'ASSOCIATED WITH' named entity 'GROUP' named entity 'VACCINATED' named entity '3 WEEKS' named entity 'COMPARED' named entity 'HSCT' named entity '217' named entity 'CONCLUSION' named entity 'DIFFERENT' named entity '0.78' named entity 'ADJUVANTED' named entity 'BACKGROUND' named entity 'TITER' named entity '28P' named entity 'TOLERANCE' named entity 'RESPONSE TO' named entity 'VACCINATION' covid:arg/fa9d5bbf9793d156a4a0f58e8dc9ba221378ee89 named entity 'TRANSPLANT RECIPIENTS' named entity '60%' named entity 'TRIGGERED BY' named entity 'ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION' named entity 'BASELINE' named entity '2860' named entity 'OBSERVED' named entity 'IMMUNOSUPPRESSIVE' named entity 'INFECTION' named entity 'RATE' named entity 'MULTIVARIATE ANALYSIS' named entity 'DAY' named entity 'INDUCED' named entity 'VACCINE' named entity 'TRANSPLANTATION' named entity 'INFECTED' named entity 'DOSE' named entity 'PATIENTS' named entity 'INFLUENZA A' named entity 'NATURAL INFECTION' named entity 'ALLOGENEIC' named entity 'INCLUDED' named entity 'PRESENT' named entity 'ANTIBODY' named entity 'MEASURED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software